US FDA clarifies how to ensure medtech trials comply with regulations
This article was originally published in Clinica
The US Food and Drug Administration has issued a guidance document that clarifies how institutional review boards (IRBs), clinical investigators and medical device and drug sponsors can ensure that clinical trials of healthcare products comply with regulations and pose minimum risk to human subjects.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.